Contributions
Abstract: EP1660
Type: ePoster
Abstract Category: Therapy - disease modifying - 26 Immunomodulation/Immunosuppression
Background: SIENA is a free algorithm, part of the FSL toolkit (www.fmrib.ox.ac.uk) that allows the direct quantification of brain atrophy from serial MR images. It has been applied in numerous studies of MS, investigating brain atrophy in people who have experienced a CIS and patients with RRMS, SPMS and PPMS.
Purpose: To determine and to compare the Percentage of Brain Volume Change of two groups of MS patients treated on Interferon B1a sc or Fingolimod.
Methods: 63 patients (16 male and 47 female) with Relapsing Remitting MS and a Kurtzke Expanded Disability Scale Score (EDSS) of 0-5.0 were included in a prospective study of Fingolimod (36 patients) or Interferon B1a sc (27 patients) in RRMS. All patients were followed up for a minimum period of 1 year. Every three months disability was assessed by different neurological scale. Percentage of Brain Volume Change (PBVC) was measured by an automated segmentation of SIENA (ABACUS).
Results: Patients on Fingolimod 0.5 mg achieved a Percentage of Brain Volume Change of -0.48±0.6%. Patients on Rebif achieved a Percentage of Brain Volume Change of -0,30±0.9%. There was no statistical difference between these two groups.
Conclusions: Although the drugs are positioned at different levels of effectiveness, this measure of whole-brain atrophy provided similar data regarding these two inmunomodulators. Further investigations are required.
Disclosure: JLRP nothing to disclose
Abstract: EP1660
Type: ePoster
Abstract Category: Therapy - disease modifying - 26 Immunomodulation/Immunosuppression
Background: SIENA is a free algorithm, part of the FSL toolkit (www.fmrib.ox.ac.uk) that allows the direct quantification of brain atrophy from serial MR images. It has been applied in numerous studies of MS, investigating brain atrophy in people who have experienced a CIS and patients with RRMS, SPMS and PPMS.
Purpose: To determine and to compare the Percentage of Brain Volume Change of two groups of MS patients treated on Interferon B1a sc or Fingolimod.
Methods: 63 patients (16 male and 47 female) with Relapsing Remitting MS and a Kurtzke Expanded Disability Scale Score (EDSS) of 0-5.0 were included in a prospective study of Fingolimod (36 patients) or Interferon B1a sc (27 patients) in RRMS. All patients were followed up for a minimum period of 1 year. Every three months disability was assessed by different neurological scale. Percentage of Brain Volume Change (PBVC) was measured by an automated segmentation of SIENA (ABACUS).
Results: Patients on Fingolimod 0.5 mg achieved a Percentage of Brain Volume Change of -0.48±0.6%. Patients on Rebif achieved a Percentage of Brain Volume Change of -0,30±0.9%. There was no statistical difference between these two groups.
Conclusions: Although the drugs are positioned at different levels of effectiveness, this measure of whole-brain atrophy provided similar data regarding these two inmunomodulators. Further investigations are required.
Disclosure: JLRP nothing to disclose